Trial Profile

Efficacy and Safety of Conversion Therapy With Sintilimab in Combination With Chemotherapy and Apatinib in Patients With Stage IV Gastric Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Therapeutic Use
Acronyms CO-STAR

Most Recent Events

03 Jul 2023 Planned End Date changed from 30 Dec 2022 to 30 Aug 2023.
03 Jul 2023 Status changed from recruiting to active, no longer recruiting.
05 Jul 2021 Planned number of patients changed from 30 to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com